A Phase II Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimer's Disease
Study of BHV-4157 in Alzheimer's Disease (T2 Protect AD)
Sponsor: Biohaven Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
Study Length: 48 Weeks
IRB Number: AAAR9079
U.S. Govt. ID: NCT03605667
Contact: Betina Idnay, RN: 212-342-5615 / bsi2102@cumc.columbia.edu
Additional Study Information: T2 Protect AD is a clinical trial testing the investigational drug troriluzole in people with mild to moderate Alzheimer's disease (AD). The study is designed to determine whether this new drug can protect against, slow down, or potentially improve memory and thinking problems that increase as Alzheimer's disease progresses.
This study is closed
Investigator
Karen Bell, MD
Do You Qualify?
Are you between the ages of 50-85? Yes No
Do you have a diagnosis of Alzheimer's Disease (AD)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Betina Idnay, RN
bsi2102@cumc.columbia.edu
212-342-5615
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE